Hoey Investments’s CRISPR Therapeutics CRSP Stock Holding History

Hoey Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100	Closed	-$4.86K	–	418
2025 Q2	$4.86K	Hold	100	–	–	﹤0.01%	280
2025 Q1	$3.4K	Buy	+100	New	+$4.24K	﹤0.01%	271
2024 Q4	–	Sell	-130	Closed	-$7.02K	–	388
2024 Q3	$7.02K	Hold	130	–	–	﹤0.01%	225
2024 Q2	$7.02K	Buy	130 +30	+30%	+$1.74K	﹤0.01%	225
2024 Q1	$6.82K	Hold	100	–	–	﹤0.01%	225
2023 Q4	$6.26K	Buy	+100	New	+$5.53K	﹤0.01%	236
2022 Q4	–	Sell	-100	Closed	-$7K	–	311
2022 Q3	$7K	Hold	100	–	–	﹤0.01%	244
2022 Q2	$6K	Hold	100	–	–	﹤0.01%	205
2022 Q1	$6K	Hold	100	–	–	﹤0.01%	191
2021 Q4	$8K	Hold	100	–	–	﹤0.01%	183
2021 Q3	$11K	Buy	+100	New	+$12.6K	﹤0.01%	165

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Hoey Investments's CRSP Position: Q3 2025 in Review

Hoey Investments sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 100 shares — an estimated $4.86K sold.

Hoey Investments first reported a position in CRSP in Q3 2021 and held it in 11 quarters. The position peaked at $11K in Q3 2021. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Hoey Investments reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Hoey Investments sold 100 CRISPR Therapeutics shares in Q3 2025, an estimated $4.86K.
Hoey Investments first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 11 quarters.
Hoey Investments's CRISPR Therapeutics position peaked at $11K in Q3 2021.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Hoey Investments's 13F filing for Q3 2025, filed 13 Nov 2025.